Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...

Verdence Capital Advisors LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% in the third quarter, according to the company in its most recent 13F ...

A $1000 investment made in November 2014 would be worth $6,540.57, or a gain of 554.06%, as of November 8, 2024, according to our calculations. This return excludes dividends but includes price ...

Analysts anticipate Halozyme Therapeutics to report an earnings per share (EPS) of $0.98. Investors in Halozyme Therapeutics ...

Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

According to Benzinga Pro, Halozyme Therapeutics's peer group average for short interest as a percentage of float is 10.61%, which means the company has more short interest than most of its peers. Did ...

Halozyme Therapeutics ( (HALO) ) has released its Q3 earnings. Here is a breakdown of the information Halozyme Therapeutics presented to its ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Halozyme (HALO – Research Report), with a ...

On Monday, Piper Sandler adjusted the stock price target for Halozyme (NASDAQ:HALO) Therapeutics (NASDAQ:HALO), increasing it to $52.00 from the previous $51.00. The firm retained a Neutral rating ...